-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Current Issue : Oncology Times - 2 year(s) ago
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New Issue Out Now! The September 5th issue features: #HodgkinLymphoma Treatment Shifts to Immunotherapy, Biological Aging Accelerated by Radiation Treatment in #BreastCancer, and more: https://t.co/pJq68H8b1y #CancerResearch https://t.co/nydGHF2fhN
-
-
Mashup Score: 0
Elizabeth Brem , MD discusses the design and outcomes of the study referred to as 1826. The study aimed to enhance outcomes and address toxicities in Hodgkin lymphoma treatment. Nivolumab’s potential benefits in comparison to brentuximab within the AVD backbone were explored. Additionally, Brem highlights the collab…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🔬 Elizabeth Brem, MD (@DrLizBrem) advances Hodgkin lymphoma treatment with Study 1826: Nivolumab vs. Brentuximab in AVD. Collaboration shines! 🤝 @ASCO @MOASC_Office @UCIrvine @UCIrvineHealth 📽️ Watch the [video]https://t.co/2AvgdDvsbV #HodgkinLymphoma https://t.co/caWHzznISN
-
-
Mashup Score: 4Hodgkin Lymphoma - Cancer Stat Facts - 2 year(s) ago
Hodgkin Lymphoma statistics
Source: seer.cancer.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#HodgkinLymphoma is most frequently diagnosed among people between 20-34 years. The median age of diagnosis is 39. Visit our Cancer Stat Facts sheet to learn more: https://t.co/jSoS2m4bCq https://t.co/CnHAqK1hZS
-
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Hodgkin lymphoma patients treated with nivolumab and AVD chemotherapy had a significantly lower risk of cancer progression than those treated with brentuximab vedotin and AVD a year after starting treatment. https://t.co/APUmMwVDj8 #Hodgkinlymphoma https://t.co/7PdwbsmV0l
-
-
Mashup Score: 0Hodgkin Lymphoma - Cancer Stat Facts - 2 year(s) ago
Hodgkin Lymphoma statistics
Source: seer.cancer.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#HodgkinLymphoma is most frequently diagnosed among people between 20-34 years. The median age of diagnosis is 39. Visit our Cancer Stat Facts sheet to learn more: https://t.co/9L6h7VgNUG https://t.co/UbrPfontiE
-
-
Mashup Score: 3
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The most comprehensive study to date of #Hodgkinlymphoma has provided fascinating insights into what tumor cells must do to survive. Researchers found that #cancercells use signals to attract certain types of immune cells and instruct them not to attack. https://t.co/hq0Vgv70aq https://t.co/sDD0HINFzc
-
-
Mashup Score: 13
Working… This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value entered is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again. The value you provided must be within the suggested range The value you provided is outside the suggested range This…
Source: redcap.mskcc.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Survivors of #HodgkinLymphoma can face difficult treatment decisions & financial tradeoffs. We want to better understand how cancer (and cancer-related costs) have affected your life so that we can provide better resources in the future. #lymsm #ayacsm 🙏https://t.co/fC5AP7vMnI https://t.co/3OWnttJyJz
-
-
Mashup Score: 1
Interview with David Henry MD
Source: PracticeUpdateCategories: Hem/Oncs, Latest HeadlinesTweet-
#Nivolumab Plus #Brentuximab Vedotin for Low-Risk Relapsed Classic #HodgkinLymphoma Check out my practice update! 👉https://t.co/9tlCmoBmg3
-
-
Mashup Score: 3Checkpoint Inhibitor Plus Chemotherapy Improves Outcomes for Hodgkin Lymphoma - News Center - 2 year(s) ago
Adding a checkpoint inhibitor to conventional chemotherapy improved outcomes for patients with relapsed or refractory classic Hodgkin lymphoma, according to a Northwestern Medicine phase II clinical trial published in JAMA Oncology.
Source: News CenterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adding a checkpoint inhibitor to chemotherapy improved outcomes for patients with relapsed or refractory classic #HodgkinLymphoma, according to @JaneWinterMD @LurieCancer, senior author of the clinical trial published in @JAMAOnc https://t.co/BKxmz6fG8J via @NUFeinbergMed #lymsm https://t.co/noxPr5Z9Lo
-
A study revealed 86.5% of patients with relapsed or refractory classic #Hodgkinlymphoma had a complete metabolic response when pembrolizumab was added to ifosfamide, carboplatin, and etoposide (ICE) #chemotherapy. Read more: https://t.co/FIPIhYpdq5 https://t.co/6CzPsVby8G